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Abstract
Background: Tobacco use is the leading cause of preventable death in Ireland with almost 6000 smokers dying
each year from smoking-related diseases. The ‘We Can Quit2’ (WCQ2) study is a pilot pragmatic two-arm, parallel-
group, cluster randomised trial that aims to explore the feasibility and acceptability of trial processes including
recruitment and to estimate parameters to inform sample size estimates needed for an effectiveness trial. This
future trial will assess the effectiveness of a community-based smoking cessation intervention for women living in
disadvantaged areas on short- and medium-term cessation rates.
Methods/design: Four matched pairs of districts (eight clusters) selected by area level of deprivation, geographical
proximity, and eligibility for free medical services will be randomised to receive either WCQ (behavioural support +
access to Nicotine Replacement Therapy (NRT)) delivered over 12 weeks by trained Community Facilitators (CFs) or
to a form of usual care, a one-to-one smoking cessation service delivered by Smoking Cessation Officers from
Ireland’s national health service, the Health Service Executive (HSE). Within each cluster, 24–25 women will be
recruited (97 per arm; 194 in total) in 4 phases with consent obtained prior to cluster randomisation. The outcome
measures will assess feasibility and acceptability of trial processes, including randomisation. Outcome data for a
future definitive intervention (biochemically validated smoking abstinence) will be collected at end of programme
(12 weeks) and at 6 months. WCQ2 has an embedded process evaluation using both qualitative and quantitative
methods. This will be conducted (semi-structured client and CF interviews, intervention delivery checklist, and diary)
to explore acceptability of trial processes, intervention fidelity, trial context, and implementation. Trial processes will
be assessed against domains of the PRECIS-2 wheel to inform a future definitive trial design.
Discussion: Data from this pilot trial will inform the design and sample size for a full cluster randomised trial to
determine the effectiveness of an intervention tailored to disadvantaged women in improving smoking cessation
rates. It will provide transferable learning on the systems and implementation strategies needed to support
effective design of future pragmatic community-based trials which address health promotion interventions for
women in disadvantaged communities.
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Background
Tobacco use is the leading cause of preventable death
globally. Almost 6000 smokers die annually in Ireland
from smoking-related diseases [1]. The Tobacco Free
Ireland Programme have set a target for Ireland to be-
come tobacco free (i.e. with a smoking prevalence rate
of less than 5%) by 2025 [2]. Although smoking rates
have dropped by 1% per year since 2015, 20% of the
population aged 15 years and over remained regular
smokers in 2018 (men 22%; women 17%) [3]. The data
confirm persistence of the health inequalities gap with
higher rates in more disadvantaged than in more affluent
areas (26% vs 16%) [3]. It is evident therefore that ‘busi-
ness as usual’ is not sufficient to affect the step change
required to reach the endgame [4].
Whereas lung cancer incidence rates in Irish males de-
clined steadily during 1994 to 2015, female rates in-
creased significantly and continue to increase [5]. More
women in Ireland are now dying from lung cancer (19%
of all cancer deaths) than breast cancer (17%) [6]. In
socio-economically disadvantaged areas, lung cancer
rates are higher in women than in men [5]. This pattern
suggests that smoking impacts on health inequalities via
gender in addition to socio-economic influences.
Research has also noted the cumulative effect of disad-
vantage on women’s smoking [7]. The intergenerational
impacts of women smoking are particularly evident in
disadvantaged communities, with increased likelihood of
potentially preventable adverse outcomes perinatally,
during infancy and childhood [8]. Measures to restrict
impact of environmental tobacco smoke in the home are
less likely to be implemented [9], and parental smoking
in the home increases the child’s chances of becoming
an adult smoker (via role modelling) which has direct
and immediate impact on children’s health [10].
Previous studies have made the case that smokers
from disadvantaged groups should be targeted for
greater efforts to support smoking cessation, with more
consideration of the role of gender in design of smoking
prevention interventions. Such efforts need to focus on
the social conditions that affect women’s lives as well as
the individual level interventions including approaches
to improve health behaviours [7].
The link between cancer and smoking among women in
Ireland, and other developed countries, has been recog-
nised by the World Health Organisation (WHO) through
the Framework Convention on Tobacco Control [8]. The
WHO has called for a gendered lens to be applied to to-
bacco control policies. Despite this, few countries
have attempted to tailor smoking cessation services to
meet the needs of women.
The national Health Service Executive (HSE) provides
smoking cessation services which are not gender-based.
This service is available to any Irish citizen. The univer-
sal components of this service are a National Quit
service, which was launched in 2014 as an interactive
smoking cessation support service delivered via phone,
web, text, and social media. These elements may be
supported by specialist smoking cessation services lo-
cally that provide face-to-face behavioural support
either individually or group based (rarely) and access to
Nicotine Replacement Therapy (NRT); however, this is
resource dependent [9]. A map of the Irish smoking
cessation services is available at the following link:
https://quit.ie/I-Want-to-Quit/Support-Services/.
WCQ
Arising from the above context and in a bid to design
and deliver an intensive, face-to-face smoking cessation
intervention tailored to women that is feasible in an Irish
context, the Irish Cancer Society (ICS) in partnership
with the National Women’s Council Ireland, and the
Institute of Public Health in Ireland developed ‘We Can
Quit’ (WCQ), a community-based smoking cessation
programme for women from socially and economically
disadvantaged communities.
The WCQ intervention was developed in accordance
with the Medical Research Council guidance for devel-
oping complex interventions, identifying the evidence
base, identifying/developing theory, and modelling
process and outcomes [10]. It was developed based on
evidence that delivery of a group programme to disad-
vantaged US women in their local communities by
trained peers (sister-to-sister) [11, 12] using behavioural
support and access to pharmacotherapy [13] resulted in
higher than expected smoking cessation rates in this
group of women. The intervention was adapted by the
ICS and HSE for an Irish setting, using a community
social-ecological model [14] and optimised in a prior
feasibility study of 39 women which showed favourable
retention and smoking cessation rates [15].
The core components of the WCQ intervention are
as follows:
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 An evidence-based smoking cessation behavioural
support programme delivered in a group setting over
12 weeks with individual follow-up as required for
women from disadvantaged communities
 Combination NRT (nicotine patches and an oral
NRT product dispensed by community pharmacists
free of charge)
 Delivery by trained community health workers to
women in their community setting
 Inclusion of a relapse prevention element
Additional non-core components include the following:
 Signposting/additional community supports by local
community health workers to participants who enrol
in the programme
 Use of social marketing strategies to promote
cultural change and promote cessation services
The principal differences with the standard HSE
programme are the tailoring of WCQ to women in a
group community setting, delivery by community lay
personnel over 12 weeks as opposed to an average of
6–7 individual sessions, and NRT provided free of
charge to all participants instead of a means-tested
service within the HSE.
The 12-week programme was modified for this pilot
cluster randomised controlled trial (RCT)—WCQ2, by
revision of the intervention manual and standardisation
of all questionnaires to include validated questions. This
protocol describes the WCQ2 RCT which incorporates
an embedded process evaluation.
Aims
The overall aim of the study is to assess the feasibility of
running a definitive randomised trial to determine
whether a community-based smoking cessation complex
intervention tailored to disadvantaged women affects their
smoking cessation rates.
Objectives
The primary objectives of the trial are as follows:
(i) To determine the feasibility and acceptability of
trial processes including randomisation of districts,
recruitment, and data collection in both
intervention and control arms
(ii) To assess data quality and completion rates for the
main outcome measures for a future definitive trial
(DT) including biochemically validated abstinence
from smoking (using salivary testing) at 12 weeks (end
of programme) and 6months (longer-term outcome)
(iii) To estimate the sample size and design for a
future DT including an estimate of the intra-cluster
correlation coefficient (ICC) to account for the effect
of ‘clustering’ in design and analysis
The secondary objectives of the trial are as follows:
(i) To test the robustness of trial design with respect
to context for delivery of the intervention,
implementation processes, and key mechanisms of
impact, from which to optimise design of a full
effectiveness trial
(ii) To develop strategies to optimise recruitment and
dissemination of findings to trial stakeholders to
inform knowledge exchange and future research
The study protocol (version 3.0, 19 October 2018) has
been developed in line with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) 2013
statement [16] (Additional file 1). Any changes to the proto-
col will be communicated to all investigators, submitted for
ethical approval, and reflected in changes to the trial registry.
Methods/design
This study is a pilot two-arm, parallel group, cluster ran-
domised trial [17]. It was designed with assistance from
the Irish Health Research Board Trials Methodology Re-
search Unit (HRB-TMRN).
Setting, recruitment, and informed consent
Cluster recruitment
Four matched pairs of urban and semi-rural districts
(eight clusters) in Dublin and Cork will be identified in ad-
vance where local communities have expressed interest in
participating via Local (Area) Advisory Groups (LAGs).
LAGs have been developed, with two in Dublin and two
in Cork, through a community engagement process initi-
ated and developed by the ICS in partnership with a com-
pany in the local community and are government funded.
They consist of the ICS, the Local Development Com-
pany, community development projects, family resource
centres, representatives from the HSE, local authorities,
local pharmacies, and other relevant community groups,
such as traveller, women, and youth organisations.
Their function is to establish support for community
action on cancer prevention, including provision of
community-based smoking cessation services for disad-
vantaged groups. In the WCQ2 study, their role will be
to direct and deliver a local recruitment strategy. They
will support the delivery of the research project in their
designated areas.
Criteria for selection of the four matched pairs of
districts by the LAGs will be similarity in terms of popu-
lation size where we aim to include approximately 8,000
- 10,000 women per district, deprivation using the 2016
Pobal HP Deprivation Index [18], and feasibility such as
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availability of a one-to-one national smoking cessation
service in the chosen areas. The selected LAGs will be
asked to provide informed consent based on their under-
standing of randomisation of their district to either an
intervention or a control arm.
Participant recruitment
Eligibility criteria
Women will be invited to take part in the study if they are
18 or over, speak fluent English, self-report as daily
smokers, indicate an interest in quitting, are deemed to
live/work/reside within easy travel distance of trial catch-
ment areas, are taking NRT, or have been prescribed bu-
propion/varenicline by the doctor at time of recruitment
and women using e-cigarettes who are current smokers.
Exclusion criteria
The following participants will be excluded from the
study: women who are pregnant or planning a pregnancy
in the near future, women already enrolled in another
smoking cessation study, those who cannot travel to lo-
cation of programme delivery, women who use NRT/bu-
propion/varenicline/e-cigarettes who have not smoked
cigarettes in the 7 days prior to recruitment, and women
who do not have the capacity to give informed consent.
Sample size
In the previous WCQ feasibility study, two areas in
Dublin were targeted with populations of 7800 and
8000, respectively. In total, 39 women signed up for the
programme, evenly split between the two areas (20 in
one area and 19 in the other), and of these, 29 women
(74%) were retained at 12 weeks follow-up [15]. Subse-
quent WCQ programmes (February 2015 to April 2016)
have demonstrated this retention rate was maintained at
62% (83/133) (Irish Cancer Society, personal communi-
cation). Therefore, based on this existing evidence, if 194
women (97 per arm) are recruited into the study, 120
women are predicted to be in this pilot study by 12
weeks [19]. This will be sufficient to identify potential
problems in practicality/feasibility, which have a 5%
probability of occurrence [20]. In the previous feasibility
study [15], 50% of women who made contact were sub-
sequently recruited to one of two 12-week programmes
running concurrently in one district (morning or even-
ing programmes), corresponding to approximately 20
women per programme. If the WCQ programme is run
sequentially in 4 districts with 2 concurrent WCQ
groups each time (i.e. 8 programmes), then there is po-
tential to recruit up to 160 women during the period
January 2018 to June 2019 (18 months), thus exceeding
the 97 required. However, the unknown parameters,
which need to be estimated from this pilot trial, are the
retention rates for the usual care districts, predicted to
have much lower rates. Data will also be used to esti-
mate the intra-cluster correlation (ICC), and this data
together with recruitment and attrition rates will be used
to inform the sample size for the DT. A flow diagram of
the study design is attached (Fig. 1). It will be conducted
in keeping with the CONSORT statement extended for
reporting cluster RCTs [21].
Criteria for withdrawal
We define ‘withdrawal of consent’ as the participant’s
voluntary termination of informed consent to participate
which they can give at any point during the conduct of
the study. All potentially eligible participants will be fully
informed about the study procedures by the participant
information leaflet which will state that participation is
voluntary and they are free to withdraw at any time
without giving a reason. We will retain participants’ data
if they withdraw from the study, unless the participant
specifically requests withdrawal of their data. All side ef-
fects will be reported to the Principal Investigator (PI).
Minor side effects will not be regarded as criteria for
withdrawal, such as skin irritation, sleep disturbance,
and headache or nausea.
Expressions of interest and informed consent
The LAGs will propose and contact relevant stake-
holders to promote the study 12 weeks in advance of
programme delivery in their selected pair of districts. In-
formation briefing sessions will be organised by ICS in
the community. Each member of the LAG will be pro-
vided with promotional material for distribution and will
be asked to promote the study through their local chan-
nels. Local press releases will be issued. LAG members
will be provided with leaflets and posters which will be
displayed in local pharmacies, GP surgeries, shops, and
dentist and community centres and disseminated outside
schools. LAG members will share posts on their organi-
sations’ social media platforms and through their statu-
tory and community contacts. The RA will assist in the
promotion of the study through information stands at
community events and at local facilities, e.g. creches.
The PI will contact the local primary care centres dir-
ectly and use radio to promote recruitment.
Six weeks in advance of programme delivery, a live
project webpage will provide information on the re-
search study and on the districts open for recruitment.
Potential participants may express interest in taking part
in the study via (i) self-registration through the project
website, by telephone or by email, or (ii) referral by their
general practitioner, local pharmacist, public health
nurse, or community worker who will complete the on-
line registration form on their behalf.
All expressions of interests received will be screened
against the inclusion and exclusion criteria. Potentially
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eligible participants will receive a project information
pack containing the participant information leaflet and
consent form. The RA will then meet with eligible par-
ticipants who have had at least 24 h to consider partici-
pation to obtain full explicit written consent including
consent for salivary sampling. Baseline demographic
data will be obtained at time of consent. Consent of re-
cruited women per cluster and across each cluster pair
will be obtained prior to breaking the randomisation
code; hence, the RA will be blinded to the allocation
(Fig. 1).
Randomisation and allocation concealment
Four matched pairs of districts (eight clusters) will be
randomised with each matched pair of clusters rando-
mised to intervention or controls in a 1:1 allocation ra-
tio. The randomisation will follow a pragmatic approach
whereby paired districts ready for the intervention will
be randomised first, followed by the next available
matched pair; this accounts for temporal changes and
will provide a balanced design.
The randomisation will be conducted remotely by the
Wellcome Trust Clinical Research Facility (CRF) inde-
pendent of the Trial Management Team, who will de-
velop a standard operating procedure for this process.
The code for each matched pair of districts will be con-
cealed and securely stored by the Wellcome CRF at St.
James’s Hospital. It will be revealed to the WCQ2 trial
team once sufficient numbers have been recruited (or by
agreement with the Trial Management Group (TMG) if
recruitment is insufficient prior to intervention delivery).
Practitioners will be informed of the area in which they
will deliver their programme by the research team, and
participants will be informed of their allocation by the
practitioners. Figure 1 displays an overview of cluster
randomisation process.
Fig. 1 Trial schema and participant flow diagram for each wave. Each pair of clusters was recruited in 1:1 allocation in one wave each (four waves in total)
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WCQ2 training
Community workers who are identified by the LAG as
being interested in delivering the WCQ2 intervention
will be trained as facilitators. These potential facilitators
may be ex-smokers themselves. The WCQ training
programme incorporates the findings of the original
WCQ development study [15] and the National Practice
Standard in Smoking Cessation [9]. It is a 3-day training
programme, co-designed and delivered by HSE specialist
trainers and Irish Cancer Society officers. The content
includes brief intervention and motivational interviewing
techniques in smoking cessation. On successful comple-
tion, new CFs are provided with a Community Facilitators
Resource Pack [22] containing recommended session
plans, resources, and monitoring and feedback tools for
the 12-week programme. Within 6months of the start of
programme delivery, CFs are also required to complete an
8–10-h online accredited National Centre for Smoking
Cessation Training (NCSCT) programme. Ongoing men-
toring and support is provided by each of the partners,
and refresher training is provided by the Irish Cancer
Society on an annual basis.
All practitioners and researchers involved in our study
will be trained in Good Clinical Practice Guidelines.
Intervention delivery
Participants randomised to the intervention will receive
12 weekly behavioural support group sessions in a com-
munity setting, e.g. resource centre, and NRT dispensed
by the community pharmacists. The group sessions are
designed to enhance positive social support systems
among peers. NRT is made available without cost to all
intervention participants.
Each programme will be delivered in a local community
facility by two trained CFs. Each session will last approxi-
mately 90min. The CFs will make proactive personal con-
tact both during and between sessions with participants
using their own language and cultural style, and provide
an opportunity to share testimonials and personal experi-
ences. They will promote social support with delivery of
emotional support (e.g. through demonstrating empath-
etic listening) among peers and will also carry out regular
carbon monoxide (CO) monitoring.
Control arm
Participants randomised to the control arm will receive
a face-to-face individual smoking cessation programme
offered by the HSE for men and women delivered by a
Smoking Cessation Officer in a community setting [9].
This was chosen as a more suitable control intervention
rather than the more readily accessible and widespread
telephone and online service due to the difficulty in
obtaining data on these services and similarity to the
WCQ in terms of providing a face-to-face service.
However, it is recognised that only a minority of women
have access to this ‘Rolls Royce’ service due to lack of
staff availability for service provision.
This programme encompasses, on average, 6–7 indi-
vidual contacts offered in a primary care centre or hos-
pital outpatient clinic. Sessions vary in duration and
mode of delivery; however, the first of these is delivered
face-to face (average session length between 30 and 45
min). Subsequent visits occur weekly or every 2 weeks
and may be conducted by telephone.
Components of the behavioural support elements of
the HSE programme include reinforcing motivation to
quit and setting a quit date, building a repertoire of
client coping strategies, providing information on the
nature of tobacco addiction and withdrawal, undertaking
regular carbon monoxide checks and giving feedback on
progress, and planning ongoing coping mechanisms and
support. Clients are informed about NRT and other
smoking cessation pharmacotherapies and are advised to
consult their general practitioner on these. HSE clients
will obtain these free of charge if they are eligible for free
General Medical Services (GMS).
HSE standard tobacco cessation training
HSE Smoking Cessation Officers are trained to offer
behavioural support and smoking cessation advice. The
intensive 2-day training they receive follows the National
Standard for Tobacco Cessation Support Programme
manual (2013). It includes face-to-face training and
online training and assessment. Most HSE Smoking
Cessation Officers have clinical backgrounds, e.g. nurs-
ing, with some psychotherapy training.
Outcomes
Primary outcome
The primary study outcome is assessment of whether the
recruitment target of 8 districts (clusters) and 194 women
is achievable within 18months of programme start. The
recruitment rate will be estimated for each wave. It will be
defined as the number of women who consent to partici-
pate (the numerator), divided by the number of eligible
women who have registered with the programme.
The four matched pairs of disadvantaged geographical
districts (clusters) will be based on the number of eli-
gible women within in each matched pair of districts
(approx. 16,000–20,000). Each pair will be randomised
to intervention or to usual care. Subsequent recruitment
of 24–25 women who consent to participate in each of
the eight districts (97 in each trial arm) will occur during
four 12-week periods. The percentage of eligible women
needed to plan a DT will be estimated.
Eligibility rates will be established from registration
details entered by either the participant or a person act-
ing on their behalf (e.g. GP) on the WCQ2 webpage.
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Contact details of potential participants will be recorded
at the point of expression of interest. Dropout rates will
be calculated between time of confirmation of eligibility
and time of consent. Number of consented women will
be recorded prior to randomisation.
Secondary outcomes
The secondary outcomes are as follows:
(i) Retention and data completion rates in each trial
arm at 12 weeks and 6 months post-quit date (set in
week 2) as a follow-up time point for a future DT
(ii) Proportion who are continuously absent from
smoking (as per Russell’s Standard) [23], at 12
weeks (primary outcome for a future DT) and at 6
months after their quit date, corroborated by
salivary cotinine and anabasine
(iii)Proportion of enrolled smokers who engage with
smoking cessation services in each trial arm
(engagement is defined as arrival for a first face-to-
face appointment with a smoking cessation adviser
and having set a quit date)
(iv)Number of sessions attended in each trial arm
(v) Proportion in each arm who report improvement in
health status measured at baseline (week 1) and 12
weeks and 6 months
Data collection will be carried out at week 1, at week 12,
and at 6 months post-quit date by the RA via a detailed
face-to face questionnaire. Socio-demographic characteris-
tics, smoking behaviour, quality of life (measured by the
Short Form-12, Version 2 survey [24]), and health status
will be recorded at week 1. Retention and data completion
rates, changes in smoking behaviour, and health status will
be collected at weeks 6 and 12. Salivary cotinine ± anaba-
sine to biochemically validate self-reported smoking cessa-
tion will be recorded at week 12 and 6/12. Attendance
sheets will be provided by service delivery providers. A
thank you payment (€20 shopping voucher) will be pro-
vided at 12 weeks and at 6-month follow-up to encourage
continued participation.
Process evaluation
The aim of the process evaluation is to test the robust-
ness of trial design with respect to context for delivery
of the intervention, implementation processes, and strat-
egies from which to optimise trial methodology for pro-
gression to a full pragmatic RCT. It will be informed by
the Medical Research Council guidance for process
evaluation of complex interventions [25] and will use
quantitative and qualitative methods to address the re-
search aims. The domains for the process evaluation will
be guided by the constructs of the PRECIS-2 tool for
assessment of applicability of trial design [26].
The following outcomes will be assessed:
(i) Acceptability of the intervention form and content
by participants and trial processes by participants
and practitioners involved in service delivery
(ii) Assessment of fidelity (the extent to which the
intervention delivered as intended)
(iii)Assessment of contextual factors affecting
recruitment and retention
(iv)Assessment of contextual factors including barriers
and facilitators to implementation
Acceptability of measures and the experience of be-
ing part of a trial will be assessed quantitatively using
the Acceptability of Intervention Measure (AIM),
Intervention Appropriateness Measure (IAM), and
Feasibility of Intervention Measure (FIM) with CFs
[27], and qualitatively by semi-structured interviews
with participants and with CFs once programme deliv-
ery is complete.
The interviews will be conducted using an interview
guide. The focus will be on the experiences of those in re-
ceipt of the programme and those involved in programme
delivery, and of being involved in a research trial. All
women participating in the intervention will be invited for
interview or will be purposefully sampled depending on
numbers [28]. The sampling procedure will target
specifically those women who were good attenders, a
mix of quitters and continued smokers who completed
the 12-week questionnaire comprehensively beforehand
(information-rich cases) as a basis to explore the re-
search questions more fully. Data collection will con-
tinue until saturation [29]; however, a minimum of 20
qualitative interviews will be conducted with partici-
pants. All CFs from each wave of programme delivery
will be interviewed jointly, where possible.
Observational field notes will be completed to assist
in the assessment of the validity of WCQ2 programme
delivery [30]. A log of attendance and any adverse ef-
fects experienced by participants will be kept by the CF.
Fidelity to training will be carried out through direct
observation of training. Fidelity to intervention delivery
will be determined using specifically designed checklists
and diaries completed by the CFs in tandem once each
session is delivered. The checklist will be based upon
the delivery of session content determined by an inter-
vention manual [22]. The diary will serve as a reflective
tool for the CFs and for the research team to determine
any deviations or adaptations in programme delivery.
Confidentiality will be assured, as participants will be
identified only by their role and will be provided with a
pseudonym. Through the combination of diary and
checklist, an assessment will be made of whether ses-
sions are delivered as planned, or any adaptations
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made, in terms of content, frequency, duration, and
coverage [31].
Reporting of the study methods will follow published
standards for undertaking and reporting qualitative re-
search (COREQ) [32].
The PRECIS-2 is a tool to assist trialists determine the
impact of their design decisions on the applicability of
an intervention in usual care [26]. The trial will be
assessed against the nine domains of the PRECIS-2
wheel: eligibility, recruitment, setting, organisation, flexi-
bility (delivery), flexibility (adherence), follow-up, pri-
mary outcome, and primary analysis. Each domain of
the PRECIS-2 tool will be scored 1 to 5 to indicate how
close to usual care the various design aspects of the trial
are (5 usual care—pragmatic, and 1 ideal world—ex-
planatory). The tool’s nine domains will be rated and
scored by the trial team during and at the end of the
intervention.
Table 1 Schedule of enrolment, intervention, and data collection: summary of key trial time points
STUDY PERIOD
Enrolme
nt
Allocation 
concealment 
broken
Post-allocation Close-out
TIMEPOINT -t1* 0 t1** t2*** t3**** tx
ENROLMENT:
Eligibility screen
Informed consent
Allocation
X
X
X
INTERVENTIONS:
Intervention group: 
WCQ2 
Control group: 
Enhanced HSE smoking 
cessation service
ASSESSMENTS*****:
Baseline questionnaire X
Follow-up I 
questionnaire
X
Follow-up II 
questionnaire
X X
Process evaluation data X X X X X 
*-t1=Baseline, **t1=Programme delivery; **t2=Follow-up I (12 weeks); ***t3=Follow-up 2 (6 months); 
*−t1 = baseline, **t1 = programme delivery, ***t2 = follow-up 1 (12 weeks), ****t3 = follow-up 2 (6 months)
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Study timelines
Table 1 displays a summary of important time points in
the feasibility study.
Data management
All personal participant information will be collected in
a separate password-protected file held by the RA. Each
participant will be allocated an identification code stored
separate from participant responses. The RA will enter
the de-identified participant responses in a purpose-built
database. A codebook for the database will be developed.
A sample of at least 20% percent of data will be checked
by the Research Fellow. If the initial check produces an
error rate above 1%, a full re-entry of data will be re-
quired. If the error rate is less than 1%, the Research Fel-
low will amend any errors in the final data sheet [33].
The de-identified data will be analysed by the trial team
and stored securely for 10 years after which they will be
destroyed. Qualitative interview audio files will be recorded
on dictaphones and immediately transferred to a password-
protected computer. Audio recordings will be sent to a
transcriber who will sign a confidentiality agreement and
transcribe the recordings verbatim. Transcripts will be
stored on a password-protected computer. Salivary samples
will be sent to a laboratory in the UK for analysis following
the procedures set out in a salivary sample protocol. Only
the trial team will have access to the trial data.
Data analysis
The pilot data will be analysed on an intention-to-treat
basis and will be mainly descriptive. A per protocol analysis
will also be carried out. A separate statistical analysis plan
will be produced. In brief, descriptive analyses will summar-
ise baseline characteristics of women in each trial arm,
eligibility rates, recruitment rates, participation, and attri-
tion rates in preparation for a full trial. Subgroup analysis
by GMS eligibility will be carried out. Elements of the RE-
AIM (Reach, Effectiveness, Adoption, Implementation, and
Maintenance) evaluation tool will provide a suitable frame-
work to structure this analysis [34]. As this study is not
powered to detect significant differences between groups,
formal significance testing will not be carried out. The
future trial primary outcome will be the comparison of the
proportions of women between groups who self-report
having quit smoking, corroborated by laboratory testing
such as salivary cotinine at end of programme (12 weeks).
The number of participants (%) experiencing cessation will
be summarised between groups. The mean change scores
(with 95% CIs) between groups on a range of question-
naires will be estimated, to assess whether these were in the
expected direction of effect. An assessment of normality
will be made on questionnaire scores, and parametric
(means and SDs) and/or non-parametric estimates and
variability (median/IQR) will be reported at baseline, 12
weeks, and 6months. Descriptive analysis of secondary out-
comes will summarise means and standard deviations for
continuous outcome measures or numbers (%) for categor-
ical data at baseline, 12 weeks, and 6months.
Thematic analysis will be used to analyse qualitative
data [35, 36]. Three members of the research team
will independently read the transcripts and the diar-
ies. Rigorous line-by-line coding will be applied, with
a focus on experiential claims and concerns [37].
Coding will be carried out manually initially and a
coding frame developed in Nvivo [37]. Patterns in the
data will be clustered into a thematic structure to
identify and categorise major themes and sub-themes.
Data saturation will be achieved as conceptualised by
inductive thematic saturation within the analyses, in
relation to the (non-) emergence of new codes or
themes [29]. Themes and sub-themes will be reviewed
and refined to ensure a coherent pattern and to recode if
necessary. Any differences in interpretation will be re-
solved through discussion. A fourth researcher with quali-
tative expertise, not involved in the trial, will review the
coding frame and apply it to a subset of approximately
10% of the transcripts and two of the four diaries to
reduce bias and ascertain the validity of the coding frame
as an analytical tool [38]. A kappa coefficient will be
calculated for inter-rater reliability. Fidelity to the
intervention delivery will be analysed by the number
and percentage of self-reported activities completed
within each session. Completeness of session content
will be noted within individual sessions and across the
programme. Differences will be noted for complete-
ness of core and optional session content.
Triangulation of the quantitative and qualitative
processes will examine the interaction between con-
text (e.g. group setting, recruitment strategy) and
implemented strategies (e.g. training, lay advocate/
statutory worker delivery) which led to certain out-
comes (e.g. participant engagement, quitting /cutting
down, participant satisfaction). The Consolidated
Framework for Implementation Research (CIFR)
which provides a menu of validated constructs that
have been associated with effective implementation
will provide a suitable theoretical framework to struc-
ture this analysis [39].
Progression criteria
This pilot trial will inform the development of a future
full DT to assess clinically meaningful and statistically
significant outcomes which may include an economic
evaluation to determine cost-effectiveness, which is not
part of the feasibility study. The ADePT decision aid will
be used alongside PRECIS-2 to aid the decision-making
process around progression to the full DT [40]. ADePT
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provides an algorithm which enables decisions to be
made in a structured way which determine whether
problems encountered were trial, or real world prob-
lems, and how they can be overcome for a future trial.
Dissemination
Once trial results are available, the trial team will pre-
pare accessible briefings for the key organisations inter-
ested in the research. These briefings will highlight
results and key lessons learned during the conduct of
the trial and inform the design of any future study. A lay
summary of results will also be prepared for trial partici-
pants, developed with Public and Patient Involvement
(PPI) representatives. Final pilot trial results will be
available via a report to the funder, submission of arti-
cles to peer-reviewed journals, an updated summary and
briefing papers for professionals and the public, presen-
tations at relevant meetings and conferences, and a sum-
mary report on the project website.
Discussion
The WCQ2 builds on the previously evaluated tailored
smoking cessation programme offered by the Irish
Cancer Society for women living in deprived areas of
Ireland [15]. WCQ2 aims to now pilot this intervention
to inform the design of a future potential DT. It is also
important to describe not only the intervention but also
the comparator, usual care. Usual care varies across
Ireland, and the face-to-face service is not universally
available. The funding and ongoing resourcing of this
service will have implications for the implementation of
a future trial.
As with any pilot trial, the main challenges are likely
to be recruitment and retention. The trial recruitment
processes, informed consent and randomisation, may act
as barriers to rapid uptake of the WCQ and HSE
programmes. Other challenges include the seasonal na-
ture of attempts to stop smoking (less likely to occur
during the summer and holiday periods, and thus,
women may be less motivated to participate in cessation
programmes). Although our trial is described as
pragmatic, there is a tension between the need to adhere
to a rigorous clinical trial design (the explanatory-
pragmatic continuum) while maintaining study condi-
tions as closely as possible to usual practice [41]. Our
use of the PRECIS-2 tool [26] will analyse the extent to
which WCQ2 is a pragmatic trial, so as to optimise the
trial’s applicability to the needs of intended stakeholders
in the full DT. The embedded process evaluation will in-
form an assessment of the acceptability of the interven-
tion and process of conducting an RCT in disadvantaged
community settings and facilitate the design of a future
DT or alternative trial design, taking into account
population size and anticipated problems of low recruit-
ment, attrition, and validated outcome measures.
Conducting this pilot study as described will enable an
assessment of the feasibility of addressing the primary
and secondary outcomes of a future DT of a smoking
cessation intervention tailored to disadvantaged women
which is delivered by trained peers in their local com-
munity. It will provide insights into how to optimise
recruitment strategies and data collection and into
the acceptability of trial measures including random-
isation. It will provide transferable learning on the
systems and implementation strategies needed to sup-
port effective design of future pragmatic community-
based trials which address health promotion interven-
tions for women in disadvantaged communities.
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